AMSTERDAM, Netherlands, Nov. 7, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, today reported strong growth in revenues for the third quarter and nine months ended September 30, 2008.
